Heng Lin

Heng Lin

Auto-generated profile, based on publicly available information

Heng Lin

Department of Oncology, Fuzhou Pulmonary Hospital of Fujian, Fuzhou, Fujian, 350008, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
JHJiaofeng Huang
Jiaofeng Huang
HLHeng Lin
Heng Lin
YWYinlian Wu
Yinlian Wu
YFYingying Fang
Yingying Fang
RKRahul Kumar
Rahul Kumar
SLSu Lin
Su Lin
Coronavirus Disease 2019 (COVID-19) has become a pandemic since March 2020. We describe here 2 cases of COVID-19 infection in a posttransplant setting. First one is a 59-year-old renal transplant recipient; the second is a 51-year-old allogeneic bone marrow transplant recipient. Both patients were on immunosuppressant therapy and had stable graft function before COVID-19 infection. After the diagnosis of COVID-19, immunosuppressive agents were discontinued and methylprednisolone with prophylactic antibiotics were initiated, however, the lung injury progressed. The T cells were extremely low in both patients after infection. Both patients died despite the maximal mechanical ventilatory support. Therefore, the prognosis of COVID-19 pneumonia following transplantation is not optimistic and remains guarded. Lower T cell count may be a surrogate for poor outcome.

2 June 2020 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
YWYinlian Wu
Yinlian Wu
HLHeng Lin
Heng Lin
QXQiang Xie
Qiang Xie
QCQun Chen
Qun Chen
YHYanfang Huang
Yanfang Huang
LCLizhou Chen
Lizhou Chen
Coronavirus disease 2019 (COVID‐19) is a novel respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), newly discovered since December 2019(Chen et al, 2020; Guan et al, 2020; Lu et al, 2020). According to WHO situation report () on 1 April, 2020, a total of 823626 cases and over 40000 death had been documented globally, rapidly evolving into a pandemic. As reported by previous studies, patients with pre‐existing health conditions are more likely to progress to severe COVID‐19 pneumonia(Guan et al, 2020; Huang et al, 2020; Yang et al, 2020; Zhao et al, 2020b). Here we report a COVID‐19 case with pre‐existing acute lymphoblastic leukemia(ALL).

25 November 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
HLHeng Lin
Heng Lin
LLLina Li
Lina Li
SLShuimei Luo
Shuimei Luo
SZSijing Zhou
Sijing Zhou
RSRuifen Shen
Ruifen Shen
XXXianhe Xie
Xianhe Xie
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Heng Lin1, 2, *, Lina Li1, *, Shuimei Luo1, Sijing Zhou1, Ruifen Shen1, Haitao Yang1, Huijuan Chen1, Xianhe Xie1 1Department of Chemotherapy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China 2Department of Oncology, Fuzhou Pulmonary Hospital, Fuzhou, Fujian, China *These authors have contributed equally to this work Correspondence to: Xianhe Xie, email: xiexianhe@yahoo.com Keywords: angiogenesis inhibitors, chemotherapy, targeted therapy, small-cell lung cancer, meta-analysis Received: July 02, 2016 Accepted: November 09, 2016 Published: November 25, 2016

3 February 2017 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
HLHeng Lin
Heng Lin
SLShuimei Luo
Shuimei Luo
LLLina Li
Lina Li
SZSijing Zhou
Sijing Zhou
RSRuifen Shen
Ruifen Shen
XXXianhe Xie
Xianhe Xie
The present study aimed to investigate the efficacy and safety of different therapeutic regimens for brain metastases (BMs) from lung cancer (LC). A total of 13 controlled trials (1,783 cases) involving chemotherapy, tyrosine kinase inhibitors or endostatin plus radiotherapy (combination group) vs. radiotherapy alone group were identified from PubMed. Compared with the radiotherapy alone group, the combination group resulted in a significant benefit for objective response rate (ORR) [risk ratio (RR), 1.38; 95% confidence interval (CI), 1.19–1.60; P<0.0001], notably prolonged the time to central nervous system progression [CNS-TTP; hazard ratio (HR), 0.71; 95% CI, 0.57–0.90; P=0.004] and progression-free survival (PFS; HR, 0.60; 95% CI, 0.44–0.83; P=0.002); however, failed in prolonging the overall survival (OS; HR, 0.80; 95% CI, 0.61–1.05; P=0.11) with a higher overall severe adverse events (AEs, Grade ≥3; RR, 2.57; 95% CI, 1.24–5.35; P=0.01). Notably, subgroup analysis demonstrated that targeted therapy plus radiotherapy possessed a superior OS compared with radiotherapy alone (HR, 0.58; 95% CI, 0.37–0.90; P=0.01) with mild non-hematological toxicity and without severe hematotoxicity. The present study demonstrated that targeted agents plus radiotherapy possessed desirable effects with mild adverse events. Secondary to best, chemoradiotherapy is an alternative option for patients without suitable molecular targets.

1 May 2024 in Combinatorial Chemistry & High Throughput Screening
Verified
Journal Article
Closed access
PDF file
HLHeng Lin
Heng Lin
CMChenhui Ma
Chenhui Ma
AZAihong Zhong
Aihong Zhong
HZHuanping Zang
Huanping Zang
WCWenxin Chen
Wenxin Chen
QXQiang Xie
Qiang Xie
Background: Anti-angiogenic agents could enhance tumor immunity response, and anti-angiogenesis plus immunotherapy has become a novel treatment option for advanced non-small cell lung cancer (NSCLC). The efficacy of this combination therapy remains controversial and obscure. Aim: We conducted a meta-analysis to evaluate the clinical efficacy and safety of this therapeutic strategy in patients with advanced NSCLC and provide more guidance for treating NSCLC clinically. Methods: A systematic literature search was performed in PubMed, Embase, Web of Science, CNKI, and Wanfang databases to identify relevant studies published up to December 2021. The primary endpoint was the objective response rate (ORR). Second endpoints were progression-free survival (PFS), overall survival (OS), and grade ≥3 AEs adverse events (AEs). The sensitivity analysis was conducted to confirm the stability of the results. STATA 15.0 was utilized for all pooled analyses. Results: Eleven studies were eventually included in the meta-analysis, involving 533 patients with advanced NSCLC. The pooled ORR rate was 27% (95% CI 18% to 35%; I2 =84.2%; p<0.001), while the pooled median PFS and OS was 5.84 months (95% CI 4.66 to 7.03 months; I2=78.4%; p<0.001) and 14.20 months (95% CI 11.08 to 17.32 months; I2=82.2%; p=0.001), respectively. Most common grade ≥3 AEs included hypertension, hand-foot syndrome, diarrhea, adrenal insufficiency, hyponatremia, proteinuria, rash, thrombocytopenia, and fatigue. Conclusion: Anti-angiogenesis combined with immunotherapy demonstrated satisfactory antitumor activity and an acceptable toxicity profile in patients with advanced NSCLC. The pooled results of our meta-analysis provided further evidence supporting the favorable efficacy and safety of this therapeutic strategy.